Skip to main content
HeartCited

Berberine Metabolic Syndrome (Cardiovascular Aspects)

B エビデンス 少なくとも1件のランダム化試験がこれを支持しており、おおむね一貫した結果が得られています。

Improves multiple metabolic parameters: glucose, lipids, BMI, waist circumference. AMPK activation addresses insulin resistance — the core driver of metabolic syndrome.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'heartcited.com'; const params = 'ingredient\u003Dberberine\u0026condition\u003Dmetabolic\u002Dsyndrome\u002Dcardiovascular'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

結論

Improves multiple metabolic parameters: glucose, lipids, BMI, waist circumference. AMPK activation addresses insulin resistance — the core driver of metabolic syndrome.

Key Study Findings

Other 6 weeks
Berberine alleviates metabolic dysfunction-associated steatohepatitis by enhancing the abundance of Akkermansia muciniphila.
Dose: None vs: MCD diet MASH model; Abx + FMT experiments Outcome: Hepatic/colonic inflammation, Akkermansia abundance 効果: None None

対象集団: MCD diet-induced MASH C57BL/6J male mice

Systematic Review n=61
Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review.
Dose: None vs: None Outcome: None 効果: None None

対象集団: Alzheimer's disease patients

Key Statistics

20

研究数

2500

参加者数

Positive

B

グレード

Referenced Papers

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

general:
500-1,500 mg/day divided TID
lipidsupport:
500 mg TID with meals

上限量: Not formally established; GI side effects limit doses >1,500 mg/day

研究で検討された用量

用量 期間 効果 N
None 6 weeks Positive --
None -- Mixed --
None -- Positive 61

推奨摂取タイミング: With meals, divided TID for sustained plasma levels; short half-life

Safety & Side Effects

報告されている副作用

  • Diarrhea (most common, usually resolves in 2 weeks)
  • Constipation
  • Flatulence
  • Abdominal pain
  • May lower blood sugar (monitor in diabetics)

既知の相互作用

  • Metformin (additive blood sugar lowering; may increase metformin levels)
  • CYP2D6 and CYP3A4 substrates (berberine is a CYP inhibitor)
  • Cyclosporine (may increase blood levels)
  • Macrolide antibiotics (may prolong QT interval)
  • Statins (complementary mechanism; monitor for additive effects)

耐容上限摂取量: Not formally established; GI side effects limit doses >1,500 mg/day

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does Berberine help with Metabolic Syndrome (Cardiovascular Aspects)?
Based on 20 studies with 2,500 participants, there is moderate evidence from clinical studies that Berberine may support Metabolic Syndrome (Cardiovascular Aspects) management. Our evidence grade is B (Good Evidence).
How much Berberine should I take for Metabolic Syndrome (Cardiovascular Aspects)?
Studies have used various dosages. A commonly studied range is 500-1,500 mg/day divided TID. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Berberine?
Reported side effects may include Diarrhea (most common, usually resolves in 2 weeks), Constipation, Flatulence, Abdominal pain. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Berberine and Metabolic Syndrome (Cardiovascular Aspects)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 20 peer-reviewed studies with 2,500 total participants. The overall direction of effect is positive.

References

  1. [1] Jiahui Xu et al.. J Nutr Biochem. 2025. Berberine alleviates metabolic dysfunction-associated steatohepatitis by enhancing the abundance of Akkermansia muciniphila. doi:10.1016/j.jnutbio.2025.110069 PubMed
  2. [2] Yufan Dai et al.. Braz J Med Biol Res. 2022. The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in … doi:10.1590/1414-431X2022e12096 PubMed
  3. [3] Noriko Shinjyo et al.. J Integr Med. 2020. Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review. doi:10.1016/j.joim.2020.01.004 PubMed

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。